title: Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
abstract: Autologous BMT (auto-BMT) has been conducted for 17 high-risk common ALL antigen (CALLA)-positive non-T cell type ALL patients. Ex vivo purging of leukemia cells from infused BM cells was performed using complement and three kinds of mouse monoclonal antibodies reactive to CALLA-positive leukemia cells: NL-1 (IgG2a), NL-22 (IgM), and HL-47 (IgM). Minimal residual leukemia cells in BM were examined by PCR method in Philadelphia chromosome (Ph1)-positive ALL cases. BCR/ABL chimeric transcript, which was positive in BM samples before purging, was shown to be absent after ex vivo purging in all three cases tested. Among four Ph1-positive cases transplanted in first CR, three cases survived in CR remission 77, 29 and 26 months after BMT, and one case died without relapse 4 months after BMT. The other four Ph1-negative cases transplanted in the first CR also remained in CR except one who relapsed. The results of minimal residual leukemia cell studies and clinical data indicate the effectiveness of our ex vivo leukemia cell purging method and auto-BMT in the early stage of CR for patients with high risk ALL.
authors.affiliation: First Department of Internal Medicine, Nagoya University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Morishima
authors.forename: K
authors.initials: K
authors.lastname: Miyamura
authors.forename: S
authors.initials: S
authors.lastname: Kojima
authors.forename: R
authors.initials: R
authors.lastname: Ueda
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
authors.forename: H
authors.initials: H
authors.lastname: Sao
authors.forename: M
authors.initials: M
authors.lastname: Tanimoto
authors.forename: R
authors.initials: R
authors.lastname: Ohno
authors.forename: R
authors.initials: R
authors.lastname: Sobue
authors.forename: M
authors.initials: M
authors.lastname: Hirano
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal; D001483:Base Sequence; D014408:Biomarkers, Tumor / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology; D016465:Bone Marrow Purging / Q000379:methods*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003165:Complement System Proteins; D003520:Cyclophosphamide; D003561:Cytarabine; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008558:Melphalan; D008875:Middle Aged; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000032:analysis; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000276:immunology; D010677:Philadelphia Chromosome; D016133:Polymerase Chain Reaction; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012074:Remission Induction; D012307:Risk Factors; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D003165:Complement System Proteins; D016044:Fusion Proteins, bcr-abl; D008558:Melphalan